The doctors involved in the studies sponsored by MD Stem Cells continue to submit articles to high quality scientific and medical journals regarding the results.  MD Stem Cells is committed to helping publish results from the studies on as frequent a basis as possible.  It is important that the medical and patient community be kept abreast of the latest results- often ground breaking, first to be published positive results in otherwise untreatable diseases.

Publishing results in journals is often an arduous process with  months of preparation, writing, revisions, submissions, peer-reviews, more revisions, editorial changes etc.  Peer-review is the process by which experts- typically physicians and scientists in the field - review, question, request explanations, clarify and verify the information in the submitted article.  Only after all has been satisfied is the article finally accepted for publication- and publication is reserved only for articles of the most importance and highest quality.   Actual publication may take several more months.   This is why publication in scientific and medical journals is so vital to progress in medicine, particularly in a leading area such as regenerative medicine.   It is the main process by which new approaches and ideas can be reviewed and verified.

Articles with larger numbers of patients with a particular disease may have results labeled as 'statistically significant'.  Statistical significance is the 'gold standard' of results in medicine.  It is the evaluation by scientific statistical methodology showing that results are not due to chance- but rather are from the particular treatment (null hypothesis).   Statistical significance in medicine is when the probability of results being from the treatment exceeds 95% ( p less than or equal to 0.05).  It is the highest level of certainty in medicine. So when doctors review an article and see 'statistically significant' they are assured that the particular approach used actually resulted in benefit for the patients.

It should be noted that although results may be statistically significant, that does not mean that every patient treated will have benefit.  Statistics apply to the group, not to an individual.

Our Publications ( so far! )

1. Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION). Stem Cell Investig 2017; 4:94.

2. Weiss JN, Levy S, Malkin A. Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a preliminary report. Neural Regen Res. 2015 Jun; 10(6): 982–988.

3. Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regen Res. 2015 Sep; 10(9): 1507–1515.

4. Weiss JN, Benes SC, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment. Neural Regen Res. 2016 [cited 2017 Nov 16];11:1512-6.

5. Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy. Neural Regen Res. 2016 Oct;11(10):1685-1694.